Detailseite
Projekt Druckansicht

Entwicklung und Analyse von effizienten und target-spezifischen antiretroviralen Rekombinasen

Fachliche Zuordnung Allgemeine Genetik und funktionelle Genomforschung
Virologie
Zellbiologie
Förderung Förderung von 2014 bis 2018
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 260115349
 
Erstellungsjahr 2018

Zusammenfassung der Projektergebnisse

Based on the here described project work we were able to demonstrate the generation of site-specific recombinases with high therapeutic relevance. In particular, we further developed recombinases Tre and Brec1 to recognize different target sequences in the long-terminal repeats (LTR) of the HIV-1 provirus and herewith, proved a first-in class strategy for eradicating the provirus in infected cells. Remarkable is the positive factor that indel formations and the emergence of resistances, in contrast to other nuclease technologies, such as CRISPR/Cas system, were not observed. Also off-target effects were not detected during the different stages of the experimental processes. Therefore, safety aspects in regard of patient treatment are being considered as very high. Based on these results, a clinical study is going to be initiated in collaboration with the HPI in Hamburg. In addition to the successful development of the HIV-1 recombinases, we were also successful in applying the technology to other therapeutic targets. Thus, the scientific team developed first recombinase variants to inactivate the human-T-cell leukemia virus (HTLV-I), another human pathogenic retrovirus. Moreover, detailed sequence analyzes of specific recombinases as well as structural biology studies on evolved recombinases provided first insights into how DNA specificity of enzymes can be rationally altered.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung